Article
Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events.
Circulation - 20 May 2003
Boekholdt S Matthijs, Agema Willem R P, Peters Ron J G, Zwinderman Aeilko H, van der Wall Ernst E, Reitsma Pieter H, Kastelein John J P, Jukema J Wouter
Abstract excerpt
BACKGROUND: Atherosclerosis is increasingly considered to be a chronic inflammatory process. We examined whether genetic variants of the toll-like receptor 4 (TLR4), which are correlated with impaired innate immunity and with progression of carotid atherosclerosis, are also associated with coronary atherosclerosis and predict the risk of cardiovascular events. METHODS AND RESULTS: Two polymorphisms of the TLR4...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.